Policy
-
From the Editor-in-Chief
Measuring a Cancer Drug’s EffectivenessSurrogate endpoints can speed up drug approvals, but are they valid measures of effectiveness?
by William G. Nelson, MD, PhD
-
Forward Look
Here Come the BiosimilarsAs patents expire on biologic drugs, cancer patients get new options.
by Stephen Ornes
-
Policy Matters
Racial and Ethnic Disparities in Multiple Myeloma Clinical TrialsThe AACR and the FDA presented joint recommendations that include broadening clinical trial eligibility and engaging the community in clinical trial recruitment.
by Kenneth C. Anderson, MD; Lola A. Fashoyin-Aje, MD, MPH; Nicole Gormley, MD; and Paul G. Kluetz, MD
-
Survivor Profile
Sharing Her StrengthDiagnosed with two cancers prior to turning 40, Rebecca Esparza uses her voice to advocate for policy changes to help people affected by cancer.
by Lindsey Konkel
-
Robotic Surgery and Cancer
Using robotic assistants for cancer surgery has become commonplace. Whether cancer patients benefit when a surgeon uses a robot remains unclear.
by Sue Rochman
-
Pushing Progress Forward
NCI Director Norman E. “Ned” Sharpless addresses disparities and maps out plans for the future amid “profound upheaval.”
by Kevin McLaughlin
-
Cancer Care Moves Forward Amid COVID-19
Following the arrival of the coronavirus in the U.S., people with cancer and their doctors are adjusting to new ways of doing things while continuing to seek and provide cancer care.
by Kate Yandell
-
Using Leftover Cancer Drugs to Help Others
Cancer drug repositories that accept unused drugs could provide an affordable source of medications for patients in need, while also providing patients left with extra drugs a way to give back.
by Jon Kelvey
-
Forward Look
Makers of E-Cigarettes Tout Role in Smoking CessationStudies provide little evidence to support this claim.
by Stephen Ornes
-
Policy Matters
Taking Steps to Address Cancer Health DisparitiesCancer outcomes are changing for the better, but advances are not affecting all patients equally.
by Brian Rivers, PhD